- OrthoPediatrics (Pending:KIDS) initiated with Buy rating and $23 (11% upside) by Stifel. Initiated at Outperform by William Blair.
- Rigel Pharmaceuticals (NASDAQ:RIGL) initiated with Buy rating and $7 (80% upside) price target by H.C. Wainwright.
- SpringBank Pharmaceuticals (NASDAQ:SBPH) initiated with Buy rating and $30 (91% upside) by B. Riley FBR.
- Bluebird bio (NASDAQ:BLUE) downgraded to In-line (Neutral) by Evercore ISI.
- Tetraphase Pharmaceuticals (NASDAQ:TTPH) price target raised to $17 from $15 by H.C. Wainwright.
- Five Prime Therapeutics (NASDAQ:FPRX) price target raised to $50 from $41 by RBC Capital Markets.
- VBL Therapeutics (NASDAQ:VBLT) price target raised to $25 from $20 by Chardan Capital Markets.
- AmerisourceBergen (NYSE:ABC) price target lowered to $86 from $93 citing near-term sentiment toward the group and risk associated with a potential entry by Amazon (NASDAQ:AMZN).
- Obalon Therapeutics (NASDAQ:OBLN) price target lowered to $15 from $20 by BTIG Research.
- HCA price target lowered to $81 from $87 by Citigroup (NYSE:C).
- Teva Pharmaceutical Industries (NYSE:TEVA) price target lowered to $14 from $20 by Susquehanna.
- Source: Bloomberg
- Now read: Teva: New CEO Starts Work
Original article